Alessandra Pontillo , Edione C. Reis , Lais T. da Silva , Alberto J.S. Duarte , Sergio Crovella , Telma M. Oshiro
{"title":"用于抗hiv免疫治疗的树突状细胞在抗hiv基因表达上表现出不同的调节作用:提高患者选择标准的新概念","authors":"Alessandra Pontillo , Edione C. Reis , Lais T. da Silva , Alberto J.S. Duarte , Sergio Crovella , Telma M. Oshiro","doi":"10.1016/j.jocit.2016.03.002","DOIUrl":null,"url":null,"abstract":"<div><h3>Objective</h3><p>As the host's genetics influences immune response to HIV-1 and progression to AIDS, similar genetic factors could affect response to immunotherapy. Differential genes expression was evaluated in clinical trial, aimed at identifying a potential predictive marker for DC quality and, finally, for therapy responsiveness.</p></div><div><h3>Methods and Results</h3><p>DC used for immunotherapy revealed a clear difference of anti-HIV genes signature, so we classified DC into two groups (A-DC and B-DC). In A-DC a limited number of genes, including inflammasome-related genes (<em>IL1B, IL18</em>), were modulated during monocytes-to-DC differentiation. A larger subset of anti-HIV genes (restriction factors, co-factors, apoptotic factors) was modulated in B-DC. This more “activated/exhausted” expression profile of B-DC apparently resulted from a more activated monocyte precursor.</p></div><div><h3>Conclusions</h3><p>These results suggest that the actual selection of HIV<sup>+</sup> individual for immunotherapy, based on clinical features, did not ensure the same DC product, and that less “activated/exhausted” DC could positively affect the outcome of immunotherapy.</p></div>","PeriodicalId":100761,"journal":{"name":"Journal of Cellular Immunotherapy","volume":"2 2","pages":"Pages 85-94"},"PeriodicalIF":0.0000,"publicationDate":"2016-11-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1016/j.jocit.2016.03.002","citationCount":"5","resultStr":"{\"title\":\"Dendritic cells used in anti-HIV immunotherapy showed different modulation in anti-HIV genes expression: New concept for the improvement of patients' selection criteria\",\"authors\":\"Alessandra Pontillo , Edione C. Reis , Lais T. da Silva , Alberto J.S. Duarte , Sergio Crovella , Telma M. Oshiro\",\"doi\":\"10.1016/j.jocit.2016.03.002\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<div><h3>Objective</h3><p>As the host's genetics influences immune response to HIV-1 and progression to AIDS, similar genetic factors could affect response to immunotherapy. Differential genes expression was evaluated in clinical trial, aimed at identifying a potential predictive marker for DC quality and, finally, for therapy responsiveness.</p></div><div><h3>Methods and Results</h3><p>DC used for immunotherapy revealed a clear difference of anti-HIV genes signature, so we classified DC into two groups (A-DC and B-DC). In A-DC a limited number of genes, including inflammasome-related genes (<em>IL1B, IL18</em>), were modulated during monocytes-to-DC differentiation. A larger subset of anti-HIV genes (restriction factors, co-factors, apoptotic factors) was modulated in B-DC. This more “activated/exhausted” expression profile of B-DC apparently resulted from a more activated monocyte precursor.</p></div><div><h3>Conclusions</h3><p>These results suggest that the actual selection of HIV<sup>+</sup> individual for immunotherapy, based on clinical features, did not ensure the same DC product, and that less “activated/exhausted” DC could positively affect the outcome of immunotherapy.</p></div>\",\"PeriodicalId\":100761,\"journal\":{\"name\":\"Journal of Cellular Immunotherapy\",\"volume\":\"2 2\",\"pages\":\"Pages 85-94\"},\"PeriodicalIF\":0.0000,\"publicationDate\":\"2016-11-01\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"https://sci-hub-pdf.com/10.1016/j.jocit.2016.03.002\",\"citationCount\":\"5\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Journal of Cellular Immunotherapy\",\"FirstCategoryId\":\"1085\",\"ListUrlMain\":\"https://www.sciencedirect.com/science/article/pii/S2352177516300024\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"\",\"JCRName\":\"\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Journal of Cellular Immunotherapy","FirstCategoryId":"1085","ListUrlMain":"https://www.sciencedirect.com/science/article/pii/S2352177516300024","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}
Dendritic cells used in anti-HIV immunotherapy showed different modulation in anti-HIV genes expression: New concept for the improvement of patients' selection criteria
Objective
As the host's genetics influences immune response to HIV-1 and progression to AIDS, similar genetic factors could affect response to immunotherapy. Differential genes expression was evaluated in clinical trial, aimed at identifying a potential predictive marker for DC quality and, finally, for therapy responsiveness.
Methods and Results
DC used for immunotherapy revealed a clear difference of anti-HIV genes signature, so we classified DC into two groups (A-DC and B-DC). In A-DC a limited number of genes, including inflammasome-related genes (IL1B, IL18), were modulated during monocytes-to-DC differentiation. A larger subset of anti-HIV genes (restriction factors, co-factors, apoptotic factors) was modulated in B-DC. This more “activated/exhausted” expression profile of B-DC apparently resulted from a more activated monocyte precursor.
Conclusions
These results suggest that the actual selection of HIV+ individual for immunotherapy, based on clinical features, did not ensure the same DC product, and that less “activated/exhausted” DC could positively affect the outcome of immunotherapy.
求助内容：
应助结果提醒方式：
京公网安备 11010802042870号
